Previous 10 | Next 10 |
home / stock / nvs / nvs articles
Novartis AG (NYSE:NVS) reportedly plans to slash up to 680 positions in its development organization, aiding in drug market launches. The...
Friday, the FDA approved Johnson & Johnson (NYSE:JNJ) Carvykti (ciltacabtagene autoleucel; cilta-cel) for relapsed or refractory mult...
Thursday, Novartis AG (NYSE:NVS) shares are trading higher after the company confirmed plans to file for Pluvicto pre-taxane la...
Scores of patients are reportedly taking legal action against pharmaceutical giants Eli Lilly And Co (NYSE:LLY) and Novo Nordisk A/S...
Key Takeaways: GenScript’s cell therapy revenue grew by 143.7% last year as a CAR-T cell therapy developed by its Legend Biotech subsidiary ...
H.C. Wainwright initiated coverage on Voyager Therapeutics Inc (NASDAQ:VYGR), noting a growing franchise of novel, highly-differenti...
On Thursday, the FDA approved BeiGene Ltd’s (NASDAQ:BGNE) approved Tevimbra (tislelizumab-jsgr) as monotherapy for adult patients w...
In a move outlined in his upcoming State of the Union address, President Joe Biden is pushing for an increase in the number of prescripti...
Biogen Inc (NASDAQ:BIIB) released interim 6-month biomarker data from the initial 29 participants in the open-label RESPOND study. The Ph...
News, Short Squeeze, Breakout and More Instantly...
2024-07-18 09:38:21 ET The stock market is a place where investors buy and sell shares of publicly traded companies. It offers opportunities for individuals and institutions to invest in various sectors of the economy. The market’s performance is influenced by economic conditions, co...
2024-07-18 04:59:00 ET Some might hesitate to invest in stocks during a bull run, like the one we are experiencing. They argue that equities are likely to be overvalued. However, it's possible to find reasonably valued picks in this environment, even among top high-quality stocks. And some ...
2024-07-12 13:15:04 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for NVS on July 12, 2024 11:58AM ET. The previous analyst recommendation was Equal-Weight. NVS was trading at $111.855 at issue of the analyst recommendation. The overall analyst consensus :...